×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Zacks Investment Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
8 hours ago
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Yahoo Finance Canada
Evaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond the conventional Wall Street...
9 hours ago
Executive Leadership Team
Viatris
Executive Leadership Team · Doretta Mistras · Paul Campbell · Andrew Enrietti · Derek Glover · Corinne Le Goff · Philippe Martin · Peter McCormick · Burt Park.
2 weeks ago
Viatris to Participate in the BofA Securities 2024 Health Care Conference
WesternSlopeNow.com
PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will...
4 days ago
US FDA declines to approve Viatris's injection for multiple sclerosis
Reuters
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating...
1 month ago
Viatris, eyeing a return to growth, taps Moderna alum as CCO
Fierce Pharma
Viatris has spent the last few years shedding its biosimilar and OTC departments, among others—but now, the company is back to making...
3 weeks ago
Viatris launches low-dose Copaxone generic formulation in Canada
Multiple Sclerosis News Today
Viatris has launched a low-dose Copaxone generic version in Canada for relapsing-remitting MS (RRMS) patients who retain the ability to...
2 weeks ago
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental ...
Viatris
PITTSBURGH and LONDON, May 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global...
5 days ago
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Reuters
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster...
1 month ago
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Yahoo Finance
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
4 days ago